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Abstract
Background: T cells producing multiple factors have been shown to be required for protection from disease progression in
HIV but we have recently shown this not to be the case in TB. Subjects with active disease had a greater proportion of
polyfunctional cells responding to ESAT-6/CFP-10 stimulation than their infected but non-diseased household contacts
(HHC). We therefore wanted to assess this profile in subjects who had successfully completed standard TB chemotherapy.
Methods: We performed a cross-sectional study using PBMC from TB cases (pre- and post-treatment) and HHC. Samples
were stimulated overnight with TB antigens (ESAT-6/CFP-10 and PPD) and their CD4+ and CD8+ T cells were assessed for
production of CD107a, IFN-c, IL-2 and TNF-a and the complexity of the responses was determined using SPICE and PESTLE
software.
Results and Conclusions: We found that an increase in complexity (i.e., production of more than 1 factor simultaneously) of
the T cell profile was associated with TB disease and that this was significantly reduced following TB treatment. This implies
that T cells are able to respond adequately to TB antigens with active disease (at least initially) but the ability of this
response to protect the host from disease progression is hampered, presumably due to immune evasion strategies by the
bacteria. These findings have implications for the development of new diagnostics and vaccine strategies.
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Introduction
Tuberculosis (TB) is a global health problem with 2 billion
people infected with the causative agent Mycobacterium tuberculosis
(MTb). Of these, 10 percent will progress to active TB disease
resulting in almost 2 million deaths per year [1]. Due to the large
discrepancy between the number of people infected and those who
progress to active disease, there appears to be an adequate
immune response in most people, at least initially. The
requirements for a protective immune response are yet to be fully
elucidated but include changes in the host immune system
together with changes in the virulence and pathogenesis of the
Mycobacterium.
MTb is an intracellular pathogen that infects macrophages and
triggers a cascade of cell-mediated immune responses. IFN-c
producing CD4+ T cells provide the major effector response to TB
but while IFN-c is required for protection against disease
progression in TB it is not sufficient on its own [2]. TNF-a has
also shown to be protective as shown by the increased incidence of
TB in patients given anti-TNF treatments for autoimmune
diseases [3]. T cells that produce multiple factors simultaneously
are termed polyfunctional T cells (PFT) and have been shown to
provide protection against disease progression in HIV-1 infection
[4] and also vaccine induced immunity [5]. Surprisingly, we have
recently shown that this same profile of response to Tuberculosis
(TB) antigens is higher in patients with active disease compared to
latent infection following stimulation with ESAT-6/CFP-10 [6]
suggesting this phenotype is not protective in the TB setting.
Variable results have been seen in other studies [7,8] dependent
on the cytokines of interest, the antigenic stimuli, the age of the
subjects and their genetic background. Not surprisingly, the
differences seen in active disease depend on disease severity and
the site of analysis: increased antigenic load in advanced
pulmonary TB has been shown to correlate with decreased IFN-
c production in the blood, but increased production in the lungs
[9]. Determination of the T cell cytokine profile at specific stages
of infection, disease and recovery is critical for development of new
diagnostics and vaccine strategies.
For a particular immune profile to be associated with TB
disease, abrogation or reversal needs to be shown following
standard treatment regimes for TB. As such, we compared the
PFT cell profiles of TB cases before and after treatment to that
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stimulation with MTb antigens. We found a significant increase in
the proportion of both CD4+ and CD8+ T cells expressing
CD107a, IFN-c and TNF-a but not IL-2 in patients with active
TB disease prior to treatment compared to post-treatment
responses. Following successful TB treatment, the proportion of
cytokine positive cells was reduced to levels equivalent to that seen
in HHC. Furthermore, subjects with active TB disease had
significantly higher levels of T cells producing 2 or more factors
which were again reduced following treatment. These findings
have implications for development of new diagnostics and vaccine
strategies.
Results
Production of CD107a, IFN-c, IL-2 or TNF-a by T cells
following MTb antigen-specific T cells is increased in TB
cases at recruitment but comparable to HHC post-
treatment
We analysed production of total IFN-c, IL-2, TNF-a and
CD107a following overnight stimulation with ESAT-6/CFP-10
(EC), PPD-T and PHA as a positive control (Table 1 and Figure 1).
Figure 1 illustrates the gating strategy used in this study with
CD4+ and CD8+ T cells assessed separately for expression of
CD107a, IFN-c, IL-2 and TNF-a (Fig. 1A). CD4+ T cells
generally had higher IFN-c and TNF-a production than CD8+ T
cells, particularly following PPD and EC stimulation while CD8+
T cells were more likely to have co-expression of CD107a with
IFN-c and/or TNF-a (Figures 1A and B).
The proportion of CD4+ or CD8+ cells positive for any one
factor following PHA stimulation was significantly increased in
TB cases before treatment compared to both HHC and cases
following treatment (p,0.01 and p,0.05 respectively; Table 1)
indicating that cells from TB cases prior to treatment are more
responsive to general stimulation. PPD and ESAT-6/CFP-10
peptides (EC) were used to elicit a TB-specific response. TB
cases had significantly higher levels of cytokine-positive cells
than HHC within both the CD4+ and CD8+ Tc e l ls u b s e t s
following EC stimulation and the CD8+ subset following PPD
stimulation (p,0.01 for all; Table 1). CD8+ levels were high
(12% positive in TB cases following both PPD and EC
stimulation) due to high expression of CD107a. The proportion
of CD4+ and CD8+ cells positive for any one factor were
significantly reduced to similar levels as HHC following
successful TB treatment (Table 1).
All our results following analysis of 4 factors were consistent
with our previous findings analysing 3-factors [5] with TB cases
generally showing significantly more expression of CD107a, a
known marker of degranulation and thus indicative of the
cytotoxic potential of the cells [10]. They also had significantly
higher production of most other cytokines than HHC in response
to TB antigens (Figure 2). Importantly, following standard
treatment for TB, these levels were similar to those seen in the
TST+ (latently infected) household contacts (HHC). Due to its
cytotoxic role, CD107a expression was higher in CD8+ compared
to CD4+ cells and was significantly higher in TB cases compared
to both post-treatment cases and HHC. We also found a
significantly higher level of TNF-a production from both CD4+
and CD8+ T cells in TB cases pre-treatment compared to both TB
cases post-treatment and HHC (Figure 2).
Expanded polyfunctional T cell responses in TB cases and
contraction following treatment
We next assessed the combination of CD107a, IFN-c,I L - 2a n d
TNF-a produced by both CD4+ and CD8+ T cells in TB cases pre
and post-treatment compared to HHC following overnight stimula-
tion with ESAT-6/CFP-10. Prior to treatment, TB cases had
significantly higher levels of CD4+ T cells producing 2 or more
factorssimultaneouslycomparedtoTB casesfollowingtreatmentand
HHC (p=0.048 and p=0.018 respectively; Figure 3A, pie graphs).
This was seen mainly for combinations involving TNF-a with
significantly higher levels of CD4+107a+IFN-c+IL-2+TNF-a+,
together with CD4+107a+IFN-c+TNF-a+,C D 4 +IFN-c+TNF-a+
and CD4+107a+TNF-a+ cells (p,0 . 0 5f o ra l l ;F i g u r e3 A ) .I n t e r e s t -
ingly, the proportion of CD4+ cells producing TNF-a alone was
significantly higher in TB cases prior to treatment compared to HHC
and this was not reduced following treatment (p,0.05 for both;
Figure 3A). However TB cases pre-treatment had significantly lower
CD4+ cells expressing IL-2 alone compared to cases post-treatment
and to HHC(p,0.001; Figure 3A). CD8+ T cellsfrom TB cases pre-
treatment also showed significantly reduced levels of cells expressing
IL-2 alone but no difference in expression of other single cytokines
(p,0.01; Figure 3B). Interestingly, there was a significantly reduced
proportion of CD8+ T cells expressing CD107a alone in TB cases
post-treatment compared to pre-treatment cases and HHC (p,0.01;
Figure 3B). Similar to the pattern seen for CD4+ Tc e l l s ,C D 8 + T
cells from TB cases pre-treatment had a significantly higher
proportion of cells producing more than 1 factor simultaneously
compared to the HHC (p=0.005; Figure 3B, pie graphs). This was
reduced but not significantly in TB cases post-treatment. This
Table 1. Proportion of CD4+ or CD8+ cells positive for any of the 4 factors (CD107a, IFN-c, IL-2 or TNF-a) following overnight
antigenic stimulation.
%CD4 %CD8
Cases Cases Contacts Cases Cases Contacts
Stimulation pre-treatment post-treatment TST+ pre-treatment post-treatment TST+
PHA 10.5[6.6–13.4] 4.1[2.1–8.5]* 4.2[2.7–6.2]** 17.3[15–24.2] 6.4[1.6–11.9]*** 5.4[3.5–7.4]***
PPD 3.7[2.2–6.3] 2.4[1.1–3.4] 2.8[0.7–4.2] 12[6.5–14.4] 2.1[1.8–3.7]** 2[0.7–4.5]**
EC 7.6[4–10] 2[1.2–3.4]** 2.3[0.7–4]** 12[5.5–13] 2.5[1.9–3.6]** 2.7[1.1–5.4]**
Data expressed as median [interquartile range (IQR)]-positive cells per subset.
*=p#0.05;
**=p#0.01,
***= p#0.001 compared to TB cases pre-treatment.
doi:10.1371/journal.pone.0011237.t001
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c+TNF-a+ and CD8+CD107a+IFN-c+ cells in the TB cases pre-
treatment (p,0.05 and p,0.001 respectively; Figure 3B).
Discussion
This study assessed the functional differences in T cell responses
to Mycobacterial antigens depending on the infection status of the
individual. We found that the complexity of the T cell response to
TB antigenic stimulation was much higher in subjects with active
TB disease than in latently infected household contacts and that
this response was contracted following successful TB treatment.
This indicates that the initial progression of TB disease is not due
to impaired T cell function but most likely is determined by
pathogen related factors which hamper the ability of the T cells to
provide protective immune responses.
Production of multiple cytokines has been associated with
protection from disease progression in HIV [4] but not TB [6].
Most studies assessing possible protective cytokines to MTb
infection have measured only single cytokines, or multiple
cytokines in the context of post-vaccination responses [7,8,11].
Furthermore, most information has been obtained using ELI-
SPOT or ELISA which do not indicate the source of cytokine
production. Given that both CD4+ and CD8+ T lymphocytes
contribute to protection against TB [12], we assessed multiple
cytokine production from both T cell subsets in response to MTb
antigens using multi-colour flow cytometry. Clearly phenotypic
analysis does not necessarily equate to actual cell function, but on
Figure 1. Representative flow cytometry profiles demonstrating the gating strategy used throughout the study. A) PBMC were
stimulated overnight and cells were analysed by flow cytometry for expression of CD107a, TNF-a, IL-2 and IFN-c. Following lymphocyte gating, CD4+
and CD8+ T cells were analysed separately for combinations of all 4 factors. B) Representative dot plots illustrating cytokine production from CD4+
and CD8+ T cells following PHA, PPD, EC and no stimulation.
doi:10.1371/journal.pone.0011237.g001
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complex functional profile prior to treatment and this is reduced to
HHC levels post-treatment. These findings implicate factors other
than effector T cells in the initial progression to active TB disease.
In more advanced TB disease T cell function has been shown to be
reduced [13] indicating that biomarkers of disease progression
need to be determined based on a correlation with bacterial load
[14]. However, further studies should also focus on the antigen-
specific response within the lung as sequestration can occur during
acute disease resulting in a low response from peripheral blood
cells compared to those from the lung [7,9]. This has implications
for TB diagnostics based on cytokine responses and supports the
premise for biomarkers to reflect different stages of disease [14].
There are other potential contributing factors to this anomaly of
the immune system: why an observed increase in T cell function in
TB disease does not equate to protection from disease progression.
These include an increase in T regulatory cells in active TB disease
[15], changes in the ratio of Th1/Th2 cytokines [9] and changes
Figure 2. Increased CD107a, IFN-c and TNF-a expression in TB cases pre-treatment and reduction post-treatment. Bar indicates
median of TB cases pre-treatment (n=12, filled circles), TB cases post-treatment (n=10, open circles) and 17 HHC (triangles). Data were analysed
using a Kruskal-Wallis ANOVA followed by Dunn’s post-test comparison and p-values indicated.
doi:10.1371/journal.pone.0011237.g002
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In this regard, we saw a significant increase in CD4+ T cells
producing TNF-a alone and also a significant decrease in cells
producing IL-2 alone, which may contribute to disease progression
despite the increase in the proportion of polyfunctional cells.
Indeed, the protective effects of TNF-a have been shown to be
dose dependent with too high levels associated with increased TB
pathology [16]. A final factor is the immuno-evasion strategies
(such as deregulation of macrophage activity) employed by the
Mycobacteria to inhibit the ability of the immune system to protect
against disease progression [18,19].
Few studies have assessed the contribution of degranulation in
the immune response to TB antigens. We wanted to analyse this
factor in our study as it is mainly produced by CD8+ T cells,
which have been shown to preferentially recognise heavily
infected cells in vitro thus suggesting a role for them in more
advanced stages of disease [3]. Indeed, a recent study has shown
distinct differences in CD4+ and CD8+ cytotoxic responses to
TB10.4 in a mouse model of TB infection [12]: similar levels
were seen early in infection with the CD4+ response decreasing
at later stages and the CD8+ response increasing. With loss of
CD4+ T cells in HIV-1 infection, a reliance on CD8+ Tc e l l si s
r e q u i r e db u tw eh a v er e c e n t l yf ound this reliance is mono-
functional with protection against development of active TB
only occurring with restoration of adequate CD4+ T cell levels
following initiation of anti-retroviral treatment [20]. In the
Figure 3. The functional profile of CD4+ and CD8+ T cells is increased in TB cases but reduced post-treatment. PBMC were stimulated
overnight using ESAT-6/CFP-10 and CD4+ and CD8+ cells were analysed by flow cytometry for different combinations of IFN-c, IL-2, TNF-a and
CD107a. Responses are grouped and colour coded according to the number of factors: White =1 function, black = any 2 factors, blue = any 3
factors and red = all 4 factors. The pie charts summarise the results shown in the dot plots indicating the combination of cytokines as a percent of
total responding cells for CD4+ (A) and CD8+ (B). Significant differences are indicated and were determined using a Kruskal-Wallis ANOVA followed by
Dunn’s post-test comparison. Pie chart segments were analysed using a permutation test and p-values indicated.
doi:10.1371/journal.pone.0011237.g003
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expression on both CD4+ and CD8+ cells following successful
TB treatment, with levels comparable to HHC. The pattern of
expression with other cytokines was quite similar between the
two subsets however CD8+ cells showed a reduced level of
CD107a following EC stimulation in TB cases post-treatment
compared to pre-treatment and HHC. The main limitations of
the present study are the relatively small sample size and the
lack of longitudinal data and these factors should be included in
future work in order to stratify the mono- and polyfunctional
CD4+ and CD8+ T cell responses according to distinct stages of
TB disease severity.
In conclusion, this study has shown that the response of T cells
to TB-specific antigens is increased and more complex in patients
with active TB disease compared to their latently infected HHC
and that these responses are contracted following successful TB
treatment. This suggests that loss of T cell function is not the initial
factor in development of active TB disease and supports the
requirement for biomarkers of TB disease to account for the stage
of disease and bacterial load.
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethical approval was obtained from
the Gambia Government/Medical Research Council Joint Ethics
Committee. All patients provided written informed consent for the
collection of samples and subsequent analysis.
Participants
This was a cross-sectional study involving 12 treatment-naive
patients with active TB, 10 patients after TB treatment and 17
Mycobacterium-exposed household contacts (HHC) that were consec-
utively recruited as part of on-going tuberculosis case contact studies
at the MRC (UK) unit in The Gambia. Subjects were considered for
inclusion if they were .15 years of age and were HIV-1 sero-
negative. All cases and contacts underwent a clinical assessment,
including a screen for malaria and inter-current illness. Tuberculin
skintests(TST;2tuberculinunites[TU],PPDRT23,SSI,Denmark)
were performed on the HHC a skin test induration of $10 mm
diameter categorised as TST positive. Subjects with active disease
were recruited into the study if they had 2 consecutive positive smears
a n dw e r ep o s i t i v eb yc h e stx - r a y .O ft h e1 2c o n fi r m e dT Bc a s e sint h i s
study, 7 had mild disease and 5 had severe disease as determined by
x-ray score. Other clinical data such as night sweats, cough duration
and weight loss were obtained from the TB cases where possible. TB
treatment consisted of 2-months intensive phase with rifampicin,
pyrazinamide, isoniazid and ethambutol followed by a 4-month
continuation phase with isoniazid and rifampicin only. 9/10 subjects
analysed at the follow-up time-point had successfully completed
treatment with one patient transferring out of the study area and thus
unavailable for sputum confirmation. Following informed consent,
10 mL of heparinised blood was taken from all subjects.
Flow cytometry
PBMC separation. Peripheral blood mononuclear cells
(PBMC) were isolated using density gradient centrifugation
according to the LeucosepH tube protocol (Greiner Bio-one, USA).
After two washes, cells were resuspended in RPMI+10% AB serum
(Sigma, USA), supplemented with penicillin/streptomycin and L-
glutamine and counted using a hemocytometer and trypan blue
exclusion.
Overnight antigenic stimulation. 2 million PBMC
resuspended in 1 mL of complete medium were added to single
wells of a 24-well plate (Nunc, Germany). Each subject had five
different stimulation set-ups: negative (media alone), positive
(PHA; 5 mg/mL), PPD-T (10 mg/mL) and ESAT-6/CFP-10
peptides (EC; 10 mg/mL). In addition, CD107a-FITC (20 mL
per well; Ebioscience, UK) was added for detection of
degranulation. Brefeldin A (10 mg/mL; Sigma USA) and
Monensin (0.7 mL/mL; Becton-Dickinson USA) were added
after 2 hours and plates incubated overnight at 37uC, 5% CO2.
Intracellular cytokine staining. Following overnight
stimulation, cells were transferred to tubes for flow cytometric
acquisition (Dako, USA). Following centrifugation (600gmax),
supernatant was carefully removed and 20 mL of previously titrated
surface marker cocktail was added (CD4-APC-Cy7, CD8-PerCP;
BDPharmingen). In addition a live-dead fixable stain was included to
enable gating out of any non-viable cells (Invitrogen, USA) Tubes
were vortexed and incubated for 15 min. at 4uC. Following washing,
150 mL of Fix/Lyse solution (BDPharmingen) was added per tube,
vortexed and incubated at 4uC for 15 min. Cells were washed again
and 500 mLo f1 6P e r m / w a s hs o l u t i o n( B D p h a r m i n g e n )w a st h e n
added; tubes vortexed and incubated for 20 min. at RT in the dark.
Following centrifugation the supernatant was carefully removed and
20 ml of cytokine cocktail added (IFN-c-APC,TNF-a-PECy7andIL-
2-PE; BDPharmingen). Tubes were again vortexed and incubated for
30 min. at RT in the dark, then washed, and cells resuspended in1%
paraformaldehyde (PFA) prior to acquisition.
Flow cytometry acquisition and analysis. At least 200,000
lymphocytes were acquired with a CyAn ADP
TM (Beckman
Coulter, USA) flow cytometer following gating according to 90u
forward and side scatter plots. FACS plots were analysed using
FlowJo software (version 6.1.1; Treestar, OR). Combinatorial
cytokine data were analysed with PESTLE (version 1.5.4) and
SPICE (version 4.1.5) software obtained from M. Roederer
(National Institutes of Health, Bethesda, MD). Percent
frequencies of the different combinations of CD107a, IL-2,
TNF-a and IFN-c+ cells following antigenic stimulation were
calculated within the total population of CD4+ or CD8+ T cells
and background subtracted (as determined from the medium
alone control). Non-specific background was extremely low when
more than one cytokine was examined. A cut-off of 0.01% was
used as described previously [21]; values below this were set to
zero.
Statistical analysis
Group medians and distributions for TB cases pre- and post-
treatment and household contacts (HHC) were compared using
the Kruskal-Wallis ANOVA with Dunn’s post-test comparison
using GraphPad Prism software version 5 (Software MacKiev).
Comparison of cytokine combinations was assessed using ANOVA
and pie graphs analysed using an in-built permutation test (SPICE
version 4.1.5).
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